Drug Type Monoclonal antibody |
Synonyms 2141 V11, 2141-V11 |
Target |
Mechanism CD40 agonists(Tumor necrosis factor receptor superfamily member 5 agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Glioblastoma, IDH-Wildtype | Phase 2 | US | 01 Sep 2024 | |
Recurrent Glioblastoma | Phase 2 | US | 01 Sep 2024 | |
Prostatic Cancer | Phase 2 | US | 28 Mar 2024 | |
Glioblastoma Multiforme | Phase 2 | US | 06 Sep 2023 | |
Malignant glioma of brain | Phase 1 | US | 09 Jul 2021 | |
Recurrent Malignant Glioma | Phase 1 | US | 09 Jul 2021 | |
Neoplasms | Phase 1 | US | 16 Aug 2019 |
NCT04547777 (ASCO2022) Manual | Phase 1 | 8 | ffhwitafxa(ebmsiwbzwb) = unkzmczphw luxgxwoqyd (rahmicirne ) | Positive | 02 Jun 2022 |